OBJECTIVE To assess treatment satisfaction, unmet treatment needs, and new vasomotor symptom (VMS) treatment expectations among women with moderate to severe VMS and physicians treating women with VMS. METHODS This noninterventional, nonrandomized survey included qualitative interviews and quantitative surveys of women and physicians in the US. Participating women had moderate to severe VMS in the past year and received ≥1 hormone therapy (HT), non-HT, or over-the-counter (OTC) treatment for VMS in the past 3 months. Participating physicians were obstetrician-gynecologists (OB-GYNs) and primary care physicians (PCPs) who treated ≥15 women with VMS in the past 3 months. Two online survey questionnaires were developed using insights from literature, qualitative interviews, and clinical experts. Menopause Symptoms Treatment Satisfaction Questionnaire (MS-TSQ) measured treatment satisfaction. Results were summarized descriptively. RESULTS Questionnaires were completed by 401 women with VMS and 207 physicians treating VMS. Among women, mean total MS-TSQ score ranges were 62.8-67.3 for HT, 59.8-69.7 for non-HT, and 58.0-64.9 for OTC treatments. Among physicians, mean total MS-TSQ scores were considerably higher for HT than for non-HT and OTC treatments (HT: 73.4-75.6; non-HT: 55.6-62.1; OTC: 49.2-54.7). Women reported "lack of effectiveness" (41.2%), and physicians reported "long-term safety concerns" (56.5%) as main features that do not meet their current treatment expectations. The majority of women and physicians would consider trying a new non-HT treatment for VMS (75.8 and 75.9%, respectively). CONCLUSIONS Treatment satisfaction and new treatment expectations were similar but with some differences between women and physicians; the need for additional treatments for VMS was identified.

中文翻译：

---

更年期引起的血管舒缩症状的治疗满意度、未满足的需求和新的治疗期望：女性和医生的意见。


目的 评估中度至重度 VMS 女性和治疗 VMS 女性的医生的治疗满意度、未满足的治疗需求和新的血管舒缩症状 （VMS） 治疗预期。方法 这项非干预、非随机调查包括对美国女性和医生的定性访谈和定量调查。参与的女性在过去一年中患有中度至重度 VMS，并在过去 3 个月内接受了 ≥1 激素治疗 （HT） 、非 HT 或非处方药 （OTC） 治疗 VMS。参与的医生是妇产科医生 （OB-GYNs） 和初级保健医生 （PCP），他们在过去 3 个月内治疗了 ≥15 名患有 VMS 的女性。使用来自文献、定性访谈和临床专家的见解开发了两份在线调查问卷。更年期症状治疗满意度问卷 （MS-TSQ） 测量治疗满意度。对结果进行了描述性总结。结果 401 名患有 VMS 的女性和 207 名治疗 VMS 的医生完成了问卷调查。在女性中，HT 治疗的平均 MS-TSQ 总分范围为 62.8-67.3，非 HT 为 59.8-69.7，OTC 治疗为 58.0-64.9。在医生中，HT 的平均 MS-TSQ 总分远高于非 HT 和 OTC 治疗 （HT： 73.4-75.6;非 HT： 55.6-62.1;OTC：49.2-54.7）。女性报告“缺乏有效性”（41.2%），医生报告“长期安全问题”（56.5%）是不符合她们当前治疗期望的主要特征。大多数女性和医生会考虑尝试一种新的非 HT 治疗 VMS （分别为 75.8% 和 75.9%）。 结论 治疗满意度和新的治疗期望相似，但女性和医生之间存在一些差异;确定了 VMS 需要额外的治疗。